Stocktoria
Benitec Biopharma Inc. BNTC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-07-11
Chart by TradingView
3/9
Piotroski F — financial health
40.56
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | $0 | $75,000 | $73,000 | $59,000 |
| Operating income | -$41.8M | -$22.5M | -$19.1M | -$17.9M | -$13.6M |
| Net income | -$37.9M | -$21.8M | -$19.6M | -$18.2M | -$13.9M |
| Operating cash flow | -$23.6M | -$19.4M | -$18.0M | -$15.9M | -$12.8M |
| Free cash flow | -$23.6M | -$19.6M | -$18.0M | -$15.9M | -$13.1M |
| Total assets | $99.6M | $52.2M | $4.5M | $6.0M | $21.4M |
| Total liabilities | $2.3M | $5.0M | $4.3M | $3.1M | $1.4M |
| Shareholders' equity | $97.3M | $47.2M | $202,000 | $2.9M | $20.0M |
| Ratios | |||||
| Operating margin | — | — | -25441.3% | -24457.5% | -23044.1% |
| Net margin | — | — | -26082.7% | -24942.5% | -23528.8% |
| FCF margin | — | — | -24017.3% | -21797.3% | -22123.7% |
| Return on assets | -38.1% | -41.7% | -438.2% | -304.8% | -64.9% |
| Return on equity | -39.0% | -46.0% | -9684.2% | -631.8% | -69.4% |
| Current ratio | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 |
| Revenue growth | — | -100.0% | 2.7% | 23.7% | -39.2% |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 40.56 (safe)
- Working capital / assets 0.971
- Retained earnings / assets -2.291
- EBIT / assets -0.419
- Equity / liabilities 42.357
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001808898 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.